Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s James Garner tells Andrew Scott about the company's quarterly achievements, including data the company presented at the American Association of Cancer Research (AACR) conference on the use of its asset paxalisib in a rare, aggressive childhood cancer. It has been a busy quarter for the company on the trials front, and news for investors is good too, with the company introducing an at-the-market financing facility in the US - a quick and efficient way of transacting on biotech shares.
Kazia Therapeutics wraps up a busy quarter presenting paxalisib data at the AACR annual meeting
